#Biotech #Podcast - Sigyn Therapeutics (OTC:$SIGY) Talks about Treatment of #Cytokine Storm Syndrome- leading cause of death related to severe #COVID19 infections and sepsis; @Sigyn_inc

 

#Biotech #Podcast - Sigyn Therapeutics (OTC:$SIGY) Talks about Treatment of #Cytokine Storm Syndrome- leading cause of death related to severe #COVID19 infections and sepsis; @Sigyn_inc 

 

Point Roberts WA, Delta BC, January 26, 2021 - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today’s special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.

 

Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ: AEMD)

 

Listen to today’s Podcast:  

https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3

 

Read this in full at https://www.investorideas.com/news/2021/biotech/01261SIGY-Cytokine-Storm-Syndrome.asp

 

Listen to Investor Ideas podcasts on Spotify

 

Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections.  It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion.”  Mr Joyce added that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.”

 

Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.

 

Continued: “We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation (NASDAQ: CTSO) which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation.”

 

Continued: “The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in Japan.  This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm.”

 

Continued: “However, it does not address inflammatory Cytokines.  Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTCMarkets: SIGY).”

 

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

Joyce also discusses his previous leadership role at Aethlon Medical, Inc. (NASDAQ: AEMD) where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) is Working on its #qTerm Device Improvements as a Preparation for its #FDA Certification Process

 #AI #Health #Stock News: GBT (OTCPINK: $GTCH) is Working on its #qTerm Device Improvements as a Preparation for its #FDA Certification Process

 

San Diego, CA, January 26, 2021 – (Investorideas.com Newswire) - GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp (“GBT/Tokenize”) , has started a series of improvements for its qTerm device as preparations for FDA certification process. The series of improvements are targeting higher measurements accuracy, reliability and compatibility with a broad spectrum of user’s usage behavior. qTerm is aimed to measure human vitals with a touch of a finger. Based on prototype testing, debugging and study, conclusions were made in order to increase the device’s accuracy and stability as expected pre-requisites towards the company’s intentions to file for FDA certification. There is no guarantee that the company or GBT/Tokenize will receive FDA certification for the qTerm. 

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01261qTerm-Preparation-FDA.asp

 

qTerm first release will include body temperature, blood oxygen and heart rate vitals. The next release is planned to include blood pressure measurement. In order to increase consistency with user’s measurement habits, the device’s sensors will be re-located to more efficient positions to enable best and consistent results. For example, different users may press their finger using different pressure, and position. The body heat sensor’s accuracy is highly dependent on its distance from the finger’s skin. A new location of the IR (Infra-Red) sensor will be defined to enable an optimum distance to accommodate different user’s pressing pressure and position. The heart rate and SPO2 (Blood Oxygen) sensor needs a direct skin contact again with proper adjustments to different user’s finger’s pressure, position and stability. An additional microchip will be installed to provide an expert algorithm to support broad user’s measuring habits, compensating for different inputs, and providing a consistent results for heart rate and blood oxygen data. The device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user's records. It is the goal for the web application to provide a geographical location and proximity alert to assist with potential health risks. The series of modifications are done as preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process is also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time.

 

"We believe these changes will significantly increase the device’s performance, accuracy, and consistency we are required to meet during the FDA certification. We believe these changes will ensure the product's safety, accuracy, and reliability along with high quality and efficiency. This technology, assuming we receive FDA certification of which there is no guarantee, is planned to be marketed and sold for personal and clinics usage also targeting it for the telemedicine arena. Another aspect is the device’s planned Artificial Intelligence technology that will be offering advanced features like real-time health statistics, analytics, monitoring and real time, geographically proximity alert to assist with avoiding health risks. The modifications also are focus on human engineering aspect in order to ensure easier usability for the vitals measurements like finger’s position pointers and physical finger’s location structural design. We put extra emphasis on making the device easy for use, mainly intuitive. Vitals results can be crucial indicators to assist with early detection of illness and we are working to improve the device’s performance and capabilities as preparations efforts for FDA clearance. It is in our R&D culture to constantly improve our technology in efforts to bring it to the highest standards and regulations, particularly in the medicine domain when it can save lives." Said Danny Rittman GBT/Tokenize and the Company’s CTO.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

 

 

 

 

Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc

 

 

 

 

Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc

 

Point Roberts WA, Delta BC, January 25, 2021 - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today’s special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.

 

  

Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ: AEMD)

 

Listen to today’s Podcast:  

https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3

 

Read this in full at https://www.investorideas.com/news/2021/biotech/01251Podcast-SIGY-CEO-Interview.asp

 

Listen to Investor Ideas podcasts on Spotify

 

Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections.  It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion.”  Mr Joyce added that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.”

 

Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.

 

Continued: “We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation (NASDAQ: CTSO) which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation.”

 

Continued: “The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in Japan.  This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm.”

 

Continued: “However, it does not address inflammatory Cytokines.  Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTCMarkets: SIGY).”

 

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

Joyce also discusses his previous leadership role at Aethlon Medical, Inc. (NASDAQ: AEMD) where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) Researching AI based, #Robotics #Technology for the Medical Field

  

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) Researching AI based, #Robotics #Technology for the Medical Field

 

San Diego, CA, January 21, 2021 – (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”) is researching AI based, robotics technology for the medial field. Due to the expected growth in the global medical robotics industry through 2023*, a wide range of robots are being developed to serve in a variety of roles within the medical environment.  Probably one of the most famous medicals robot is the da Vinci Surgical System**, that was approved by the FDA in 2000. This system is designed to perform minimally invasive surgeries and is controlled by a surgeon from a console.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01211Robotics-Technology-Medical-Field.asp

 

GBT is commencing new research that is targeting medical application robotics, empowered by its AI system. In this research, the Company will focus on the innovation and technological advancements that is offered by AI to enable medical robots achieving higher standards. Using AI technology, robots can perform minimally invasive procedures with high accuracy and precision. For example, performing laser incisions on soft tissue, especially for microsurgeries. Using expert system guidance, one of the research goals, is to perform robotic based laser incisions simulation based on surgeon high level commands where an AI engine controls a high precision laser beam to achieve a desired incision shape, length, and depth. Another planned topic to be researched is robotic assistance for biopsies where under robotic guidance a surgeon can performs a biopsy based on 3D imaging of the area. The Company plans to develop simulated procedures and flows to be tested for further medical purposes.

 

“The field of robotics is under constant development in many areas of our daily lives. One of the popular fields that robotics researchers invest major efforts, is the medical arena. Today’s robots can take patient’s vitals, assist with prosthetics, perform an endoscopy (looking inside the human body typically via Camera) and complex surgeries. As the demand for less invasive, less painful, high precision procedures is rapidly growing, we will be evaluating our AI system for these types of procedure. Our goal is to utilize a high precision mechanical arm based robotic system in simulated medical procedures supervised by an expert system. The plan is to investigate into soft tissues ultra-fine laser incisions, 3D imaging, and intelligent navigation to organs sites of interest. Our goal is to develop low and high level programs to command robotic mechanism for various physicians assisting tasks. Our research will involve full robotic automation, a physician assistant, and a combination of both. The research is planned to be on-going and we plan to produce technical papers with conclusions and results. Based on our results, we will then seek commercial partners in this domain,” said Danny Rittman the Company’s CTO.

 

 *Source: Medical Robotics Market To Reach Over US$ 20 Bn By 2023 - Credence Research

**   Source:  da Vinci Surgical System - Wikipedia

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories